Corey J. Langer

发表

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

J. Crowley, J. Jett, D. Gandara, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

S. Novello, L. Paz-Ares, C. Langer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme.

W. Curran, B. Movsas, C. Langer, 2001, International journal of radiation oncology, biology, physics.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.

C. Langer, F. Ottery, J. Hoffman, 2001, Nutrition.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

M. von Mehren, D. Camidge, L. Chow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

T. Clackson, A. Shaw, S. Gettinger, 2013 .

Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx.

W. Curran, A. Hanlon, L. Coia, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

R. Ozols, P. Engstrom, S. Litwin, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

F. Kabbinavar, L. Fehrenbacher, D. Jablons, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.

R. Ozols, P. O'dwyer, R. Comis, 1995, Seminars in oncology.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.

S. Litwin, L. Weiner, C. Langer, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Staging and prognosis in lung cancer: making the complex accessible.

C. Langer, Corey J. Langer, C. Langer, 2001, Cancer treatment and research.

Changing patterns of practice in the management of nasopharynx carcinoma (NPC): Analysis of the National Cancer Database (NCDB).

K. Ang, R. Weber, J. Cooper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Ying Cheng, B. Halmos, H. Borghaei, 2020, Cancer.

A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).

A. Szczesna, P. Zatloukal, A. Każarnowicz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.

W. Curran, R. Komaki, W. Sause, 2005, International journal of radiation oncology, biology, physics.

Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.

W. Curran, P. Rubin, L. Coia, 2000, International journal of radiation oncology, biology, physics.

Comparative Effectiveness of Carboplatin-Pemetrexed With vs Without Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer

A. Vachani, S. Bagley, Suzanna M. Talento, 2019 .

Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma.

P. O'dwyer, C. Langer, N. Rosenblum, 1991, Gynecologic oncology.

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.

M. Socinski, S. Dakhil, I. Okamoto, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.

C. Langer, R. Mick, R. Cohen, 2022, Clinical lung cancer.

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer.

C. Langer, C J Langer, Corey J. Langer, 1999, Seminars in radiation oncology.

Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients.

A. Hanlon, R. Padmore, J. Ridge, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2014 .

Cutaneous malakoplakia simulating relapsing malignant lymphoma

R. Scher, Corey J. Langer, Juan P. Palazzo, 1990, Journal of cutaneous pathology.

Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.

M. Millenson, B. Movsas, C. Langer, 2000, Lung cancer.